[ad_1]
Ozempic used to assist remedy arthritis ache: Report
Fox News medical contributor Dr. Marc Siegel joined ‘Fox & Friends’ to debate his tackle Ozempic getting used to remedy arthritis ache and why some docs are warning some medicines can have an effect on warmth sensitivity.
Semaglutide medicines — similar to Ozempic, the favored diabetes drug — have been linked to a diminished threat of Alzheimer’s illness for sure teams.
A brand new research, which was led by researchers at Case Western Reserve University in Cleveland, Ohio, revealed that sufferers who had been prescribed semaglutide had a “significantly lower risk” of creating Alzheimer’s in comparison with these taking different sorts of anti-diabetic medicines, based on a press launch.
The researchers analyzed three years of medical data for practically a million kind 2 diabetes sufferers within the U.S.
NEW ALZHEIMER’S RESEARCH REVEALS ‘QUIET’ PHASE OF THE DISEASE, BEFORE SYMPTOMS APPEAR
The findings had been printed in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association on Thursday.
Semaglutide medicines have been linked to a diminished threat of Alzheimer’s illness for sure teams. (iStock)
“Our study provides promising real-world evidence suggesting that semaglutide could be beneficial in preventing or slowing down the development of AD,” lead creator and biomedical informatics professor Rong Xu advised Fox News Digital.
“The underlying mechanisms remain unknown, and future mechanistic studies and clinical trials are necessary to confirm the effects.”
ALZHEIMER’S DISEASE COULD BE SLOWED BY BOOSTING A CERTAIN PROTEIN IN THE BRAIN, RESEARCHERS SAY
Alzheimer’s is the seventh-leading reason for dying within the U.S., based on the Centers for Disease Control and Prevention, taking round 120,000 lives annually.
Unlocking potential advantages
Semaglutide, the lively ingredient in Novo Nordisk’s Ozempic, is a GLP-1 molecule that regulates blood sugar in diabetes sufferers.
It can be the lively ingredient in Wegovy, Ozempic’s counterpart that’s used to deal with weight problems.
Semaglutide, the lively ingredient in Novo Nordisk’s Ozempic, is a GLP-1 molecule that regulates blood sugar in diabetes sufferers. (REUTERS/Hollie Adams/File Photo)
The findings counsel that there could be potential useful results of semaglutide in stopping or slowing down the event of Alzheimer’s in high-risk populations, similar to sufferers with kind 2 diabetes, Xu famous.
“This can provide some guidance in the choice of anti-diabetic medications for diabetes management and, at the same time, for preventing Alzheimer’s disease,” she mentioned.
MEAT CONSUMPTION LINKED TO HIGHER TYPE 2 DIABETES RISK IN OBSERVATIONAL STUDY
Dr. Sue Decotiis, MD, a New York City weight-loss physician, mentioned she was not shocked by the research’s discovery of the additional GLP-1 advantages.
“We know that GLP-1 drugs treat insulin resistance, which has a positive impact on the whole body – cardiovascular health, neurovascular health, decreased risk of stroke and better cognitive function,” Decotiis, who was not concerned within the analysis, advised Fox News Digital.
Semaglutide can be the lively ingredient in Wegovy, Ozempic’s counterpart that’s used to deal with weight problems. (Michael Siluk/UCG/Universal Images Group by way of Getty Images)
Dr. Brett Osborn, a Florida neurosurgeon and longevity physician who usually prescribes Ozempic to his sufferers, mentioned this research reinforces how metabolic well being influences neurodegeneration.
“The connection becomes even more apparent when considering the links between obesity, chronic inflammation and conditions like Alzheimer’s disease, often referred to as ‘type 3 diabetes’ due to its association with insulin resistance in the brain,” Osborn, who additionally was not concerned in Case Western’s analysis, advised Fox News Digital.
“GLP-1s treat insulin resistance, which has a positive impact on the whole body – including better cognitive function.”
In people with diabetes, a byproduct of insulin resistance is a rise in irritation, Osborn famous, which is a “key driver” of neurodegeneration and cognitive decline.
“This suggests that effective management of insulin resistance and systemic inflammation reduction may be pivotal in slowing or preventing neurodegenerative diseases,” he mentioned.
‘Shifting the paradigm’
Osborn agrees that the preventive results of GLP-1 medicine will seemingly prolong throughout varied circumstances.
“These drugs will ultimately be employed not just for diabetes, but as preventative and therapeutic agents for nearly all non-infectious age-related diseases, as well as conditions like alcoholism and drug addiction,” he mentioned.
In people with diabetes, a byproduct of insulin resistance is a rise in irritation, which is a “key driver” of neurodegeneration and cognitive decline, based on a physician. (iStock)
While the research doesn’t declare that GLP-1s are a remedy for Alzheimer’s, Osborn mentioned, “It shifts the paradigm by addressing the underlying risk factors for Alzheimer’s rather than just its symptoms.”
“It suggests a more comprehensive approach — one that tackles insulin resistance, obesity and inflammation,” he went on.
CLICK HERE TO GET THE FOX NEWS APP
By bettering insulin sensitivity and lowering irritation, these medicines could present direct advantages for not solely the mind, however the whole physique, he urged.
“After all, most age-related conditions share common underpinnings and vary only by which part of the body is affected,” Osborn mentioned. “It’s simply a matter of geography.”
Alzheimer’s is the seventh-leading reason for dying within the U.S., based on the Centers for Disease Control and Prevention, taking round 120,000 lives annually. (iStock)
Decotiis mentioned she expects to see “more and more widespread benefits” from utilizing this class of medication, however that extra research are wanted to show that they sluggish the development of Alzheimer’s.
“There needs to be a clear indication from the FDA to use these drugs for Alzheimer’s specifically in order for them to be covered by insurance,” she added.
“Most age-related conditions share common underpinnings — it’s simply a matter of geography.”
Xu reiterated that these findings “cannot be used to justify off-label prescription of semaglutide for Alzheimer’s disease prevention and treatment.”
“For this to happen, randomized clinical trials are necessary,” she mentioned.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The researcher additionally acknowledged that the research had some limitations.
“This is a retrospective cohort study with inherent limitations related to uncontrolled or unmeasured confounding and biases,” she mentioned.
“These drugs will ultimately be employed not just for diabetes, but as preventative and therapeutic agents for nearly all non-infectious age-related diseases, as well as conditions like alcoholism and drug addiction,” a physician predicted. (iStock)
“Further research into semaglutide’s use will need to be further investigated through randomized clinical trials so alternative drugs can be tested as potential treatment for this debilitating illness.”
The research obtained funding from the National Institute on Aging and the National Center for Advancing Translational Sciences.
For extra Health articles, go to www.foxnews.com/well being
When contacted by Fox News Digital, Ozempic maker Novo Nordisk issued the next assertion.
“Novo Nordisk welcomes independent research investigating the safety, efficacy and clinical utility of our products.”
An organization spokesperson additionally said that Novo Nordisk is conducting its personal analysis into the effectiveness of oral semaglutide in early Alzheimer’s illness, with anticipated completion in 2025.
[ad_2]
Source hyperlink